Merck said it will buy Verona Pharma for $10 billion to bolster its lung-disease business and help replace the expected loss ...

Synchrony Medical announced that it received FDA 510 (k) clearance for its LibAirty airway clearance system.

The deal gives Merck access to Verona Pharma’s new chronic obstructive pulmonary disease medication Ohtuvayre.

Dupilumab reduces COPD exacerbations and Type 2 inflammation biomarkers, with strongest benefit in patients with high ...

Frequent consumption of a common drug that acts on the nervous system and treats a range of ailments may lead to faster ...

The move bolsters Merck's lineup as it braces for the 2028 loss of patent exclusivity for blockbuster cancer drug Keytruda.

COPD, or chronic obstructive pulmonary disease, affects more than 30 million Americans, yet many have never heard of it. COPD ...

The CAAT governance board recommends transitioning from the COPD Assessment Test to the CAAT and using it for patients with ...

Global Phase 2 clinical trial, VENTURE, to evaluate the efficacy and safety of verekitug administered every 12 or 24 weeks in ...

Merck said the deal is valued at $107 per ADS, a 23% premium to Verona’s closing price yesterday.